Monte Rosa Therapeutics annual current ratio
2020
2021
2022
2023
2024
2025
Monte Rosa Therapeutics Current Ratio Growth & History (GLUE)
Monte Rosa Therapeutics's current ratio was 6.12 for fiscal 2025.
View full Monte Rosa Therapeutics company overviewMonte Rosa Therapeutics annual current ratio history
| Fiscal year | Period ended | Current ratio | Change | Growth |
|---|---|---|---|---|
| 2025 | 2025-12-31 | 6.12 | 3.72 | +154.61% |
| 2024 | 2024-12-31 | 2.40 | −2.66 | −52.56% |
| 2023 | 2023-12-31 | 5.07 | −5.72 | −53.01% |
| 2022 | 2022-12-31 | 10.79 | −10.17 | −48.51% |
| 2021 | 2021-12-31 | 20.96 | 19.47 | +1307.37% |
| 2020 | 2020-12-31 | 1.49 | — | — |
Monte Rosa Therapeutics quarterly current ratio
Q4.20
Q2.21
Q3.21
Q4.21
Q1.22
Q2.22
Q3.22
Q4.22
Q1.23
Q2.23
Q3.23
Q4.23
Q1.24
Q2.24
Q3.24
Q4.24
Q1.25
Q2.25
Q3.25
Q4.25
Q1.26
Q2.26
| Fiscal quarter | Period ended | Current ratio | Change | YoY change |
|---|---|---|---|---|
| Q2 2026 | 2026-06-30 | 10.58 | 3.43 | +47.91% |
| Q1 2026 | 2026-03-31 | 9.54 | 3.93 | +69.98% |
| Q4 2025 | 2025-12-31 | 6.12 | 3.72 | +154.61% |
| Q3 2025 | 2025-09-30 | 6.54 | 0.51 | +8.40% |
| Q2 2025 | 2025-06-30 | 7.16 | 0.59 | +9.04% |
| Q1 2025 | 2025-03-31 | 5.61 | 0.79 | +16.42% |
| Q4 2024 | 2024-12-31 | 2.40 | −2.66 | −52.56% |
| Q3 2024 | 2024-09-30 | 6.03 | −2.06 | −25.43% |
| Q2 2024 | 2024-06-30 | 6.56 | −4.34 | −39.81% |
| Q1 2024 | 2024-03-31 | 4.82 | −6.91 | −58.89% |
| Q4 2023 | 2023-12-31 | 5.07 | −5.72 | −53.01% |
| Q3 2023 | 2023-09-30 | 8.09 | −5.46 | −40.29% |
| Q2 2023 | 2023-06-30 | 10.90 | −9.21 | −45.78% |
| Q1 2023 | 2023-03-31 | 11.73 | −13.92 | −54.28% |
| Q4 2022 | 2022-12-31 | 10.79 | −10.17 | −48.51% |
| Q3 2022 | 2022-09-30 | 13.55 | −15.53 | −53.40% |
| Q2 2022 | 2022-06-30 | 20.11 | −13.10 | −39.44% |
| Q1 2022 | 2022-03-31 | 25.65 | — | — |
| Q4 2021 | 2021-12-31 | 20.96 | 19.47 | +1307.37% |
| Q3 2021 | 2021-09-30 | 29.08 | — | — |
| Q2 2021 | 2021-06-30 | 33.20 | — | — |
| Q4 2020 | 2020-12-31 | 1.49 | — | — |
Monte Rosa Therapeutics current ratio trends
Over the last five fiscal years, Monte Rosa Therapeutics's current ratio increased from 1.49 to 6.12, a change of 4.63. The latest reported quarter, Q2 2026, shows 10.58.
About the metric
What the current ratio means
The current ratio compares short-term assets with obligations due within roughly one year. A higher ratio generally indicates more short-term balance-sheet coverage, but normal levels vary by industry and business model.
Calculation and source
How the current ratio is calculated
TickerStat calculates the current ratio as SEC-reported current assets divided by SEC-reported current liabilities for the same balance-sheet date. Periods without a positive current-liability value are omitted. Fiscal periods can differ from calendar years, so exact period-end dates are included.
Review Monte Rosa Therapeutics source filings ↗